Prostate Cancer

Biomarker Combo Could Predict Prostate Cancer Survival

A combination of biomarkers has shown promise as a surrogate for survival in clinical trials of metastatic castration-resistant prostate cancer. Image © Eugene Sim /

Prostate Cancer

At worst radical prostatectomy is equal to radiation therapy in operable very-high-risk prostate cancer, and there are accumulating data to suggest that a surgery-first approach is better induction for multimodal therapy.

It is our opinion that surgery is inappropriate for very-high-risk prostate cancer and that a combination of EBRT and ADT should be the preferred treatment modality.

The STAMPEDE trial suggests that survival can be improved in metastatic prostate cancer patients with the addition of docetaxel to frontline hormonal therapy.

Disease progression among prostate cancer patients starting androgen deprivation therapy (ADT) was delayed by 10 months in patients already receiving statins.

Men with metastatic castration-resistant prostate cancer that had mutations in DNA repair genes were more likely to respond to the PARP inhibitor olaparib.

Too many people are being screened, diagnosed, and treated for certain types of cancer, according to two cancer researchers.

Adding cixutumumab to ADT did not significantly increase the undetectable PSA rate in men with newly diagnosed metastatic hormone-sensitive prostate cancer.


Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.